Projects drug rebate savings of $103 mil. for FY 1993 that began on July 1, based on current receipts. The state projects drug ingredient expenditures of about $780 mil. over the year. Pharmaceutical proposals on the table to help break the state's current budget impasse include raising the minimum rebate level to 25%; adding a "supplemental" rebate to the current rebate; selective contracting with pharmacies; and also therapeutic substitution ("The Pink Sheet" May 11, p. 4).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth